Esperion Therapeutics (ESPR) Posts Wider Q1 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Esperion Therapeutics (ESPR) Posts Wider Q1 Loss

ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update

May 4, 2021 4:01 PM EDT

U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price

Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets

Secured Major Medicare Part D Contract Covering Approximately 8.5 Million Lives

Strengthened Balance Sheet with $80 Million from Expanded Daiichi Sankyo Agreement and Exercise of Third Tranche of the Oberland Capital Funding Agreement

ANN ARBOR, Mich., May 04, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR), the lipid management company, today reported... More